Hem Test 2: Chemo Pharm 1

Front 1

Cell cycle non-specific agents

Back 1

effects at all stages
ex: alkylating, anthracyclines, nitrosoureas, Platinum agents

Front 2

Cell Cycle specific agents

Back 2

antimetabolites, vincas, taxanes

Front 3

Mechanism of alkylating agents

Back 3

direct crosslinking of base pairs

Front 4

Alkylating agent toxicities

Back 4

myelosuppression
N/V
secondary malignancies
infertility
hemorrhagic cystitis

Front 5

Med to avoid hemorrhagic cystitis

Back 5

mesna

Front 6

Which platinum compounds cause peripheral neuropathies?

Back 6

Oxaliplatin (and cold sensitivity)

Front 7

Which platinum compounds cause nephrotoxic and N/V toxicities?

Back 7

cisplatin

Front 8

Which platinum compounds can cause thrombocytopenia toxicity?

Back 8

carboplatin

Front 9

Toxicities of nitrosoureas

Back 9

pulmonary
myelosuppression
N/V
phlebitis
CNS

Front 10

What specificity do antimetabolites have in the cell cycle?

Back 10

S phase

Front 11

2 main folate antagonists?

Back 11

MTX (w/ leucovorin), pemetrexed (w/ folic acid/B12)

Front 12

Main toxicities of MTX?

Back 12

mucositis
myelosuppression
can have renal precipitates

Front 13

Mechanism of MTX

Back 13

inhibition of DHFR

Front 14

2 main pyrimidine analogues

Back 14

fluorouracil & capecitabine (oral prodrug)

Front 15

Dose limiting toxicities for 5-FU

Back 15

GI, myelosuppression (bolus), used with leucovorin

Front 16

How does leucovorin supplement 5-FU?

Back 16

inc binding affinity to thymidylate synthetase

Front 17

Pyrimidine antagonist and toxicities?

Back 17

cytarabine (Ara-C)

tox.: cerebellar toxicity, conjunctivitis

Front 18

purine antagonist (main 3)

Back 18

6-mercaptopurine
gemcitabine
bendamustine (2 MOA: alkylating and antimetabolite)

Front 19

Vinca alkaloids are what drug class? What phase of cell cycle?

Back 19

Microtubule targeting agent; M-phase cell cycle (MT destruction)

Front 20

Which vinca alkaloid has greater myelosuppressive toxicity?

Back 20

vinblastine

Front 21

Key warning for MT targeting agents?

Back 21

Do not administer intrathecally

Front 22

taxanes are what drug class? How do they differ from vinca alkaloids?

Back 22

MT targeting agents, MT stabilization v. destruction in vinca

Front 23

Toxicities of Taxanes

Back 23

myelosuppression
peripheral neuropathies
hypersensitivity

Front 24

What causes the hypersensitivity reaction with taxale tx?

Back 24

the delivery package

Front 25

What is ixabepilone similar to? How do they differ?

Back 25

Similar to taxanes, but greater potency

Front 26

MOA of Topo I inhibitors

Back 26

blocks relaxing of supercoiled DNA (blocks transcription)

Front 27

MOA of Topo II inhibitors

Back 27

blocks recoiling of DNA after transcription

Front 28

Topo I inhibitor ex? toxicity?

Back 28

Camptothecins

Toxicity includes myelosuppression, dirrhea

Front 29

Topo II inhibitor ex? toxicity?

Back 29

etoposide (can cause hypotension)

Toxicity: myelosuppression, secondary malignancies (AML), dose dependent mucositis

Front 30

MOA of anthracyclines

Back 30

intercalate DNA and inhibit Topo, can include free radical damage

Front 31

Anthracycline drugs

Back 31

doxorubicin, daunorubicin, epirubicin, mitoxantrone

Front 32

Toxicities of anthracyclines

Back 32

Main toxicity: heart failure (dose-dependent)
myelosuppression
mucositis
extravasation (blistering, necrosis, requires sx)

Front 33

Differentiation agents for APL

Back 33

ATRA
Arsenic trioxide (only w/ shorter QT)

Front 34

Bleomycin is what type of drug?

Back 34

antitumor antibiotics (w/ dactinomycin and mitomycin)

Front 35

MOA of L-asparaginase; toxicity?

Back 35

depletes asparaginase, which is needed for ALL growth

check pancreatitis, DIC

Front 36

Toxicity of bleomycin

Back 36

pulmonary fibrosis, interstitial pneumonitis

(causes oxygen free radicals)

Front 37

Bortezomib is what type of drug? MOA?

Back 37

proteasome inhibitor; disrupts regulatory proteins needed for tumor growth

Front 38

Toxicities of bortezomib

Back 38

fatigue
neuropathy
thrombocytopenia

Front 39

MOA of Immunomodulating agents?

Back 39

antiangiogenesis (VEGF), also inhibits CAMs

Front 40

Toxicities of Imids

Back 40

neuropathy
thromboembolism
constipation

Front 41

Immune based therapies can cause what toxicities?

Back 41

flu-like, depression

Front 42

2 classes of Breast cx therapy

Back 42

anti-estrogens
aromatase inhibitors

Front 43

4 classes of prostate cx therapy

Back 43

antiandrogens
LHRH agonists (cause tumor flare)
GnRH antagonist
CYP17 inhibitors

Front 44

4 types of monoclonal antibodies, from least reactive to most reactive

Back 44

human (mumab), humanized (umab), chimeric (imab), murine (onab)

Front 45

Rituximab target?

Back 45

CD20 (lymphoma)

Front 46

Trastuzumab target?

Back 46

Her-2 (breast cx)

Front 47

Cetuximab target?

Back 47

EGFR (solid tumors)

Front 48

Bevacizumab target?

Back 48

VEGF (solid tumors)

Front 49

Cetuximab toxicity?

Back 49

severe hypersensitivity reaction
acneiform rash (better survival)

Front 50

Bevacizumab toxicity?

Back 50

proteinura
GI perforation

Front 51

Acneiform rash present in what two therapies?

Back 51

Tyrosine kinase inhibitors
EGFR directed therapies (like cetuximab)